Evaluation of VCH-759 monotherapy in hepatitis C infection

Journal of Hepatology

Volumn 51, Issue 1, 2009, Pages 39-46

  Cooper, Curtis ^a   Lawitz, Eric J ^b   Ghali, Peter ^c   Rodriguez Torres, Maribel ^d   Anderson, Frank H ^e   Lee, Samuel S ^f   Bédard, Jean ^g   Chauret, Nathalie ^g   Thibert, Roch ^g   Boivin, Isabel ^g   Nicolas, Olivier ^g   Proulx, Louise ^g  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Alamo Medical Research   (United States)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d Fundación de Investigacion de Diego   (United States)

^e Liver and Intestinal Research Centre   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g ViroChem Pharma Inc   (Canada)

Author keywords

Antiviral activity; Non nucleoside NS5b inhibitor; Pharmacokinetics; Proof of concept study; Safety and tolerability; Variant identification

Indexed keywords

ANTIVIRUS AGENT; PLACEBO; UNCLASSIFIED DRUG; VCH 759; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; FLATULENCE; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; SIDE EFFECT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOMITING;

ADULT; ANTIVIRAL AGENTS; CARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; THIOPHENES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 67349148535     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.03.015     Document Type: Article

References (20)

1. Rice C. Flaviviridae: the viruses and their applications. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Field virology (1996), Lippincott-Raven Publishers, Philadelphia 931-960
2. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., and Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999) 110-113
3. Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov 1 (2002) 911-916
4. De Francesco R., Tomei L., Altamura S., Summa V., and Migliaccio G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 58 (2003) 1-16
5. Kolykhalov A.A., Mihalik K., Feinstone S.M., and Rice C.M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol 74 (2000) 2046-2051
6. Biswal B.K., Cherney M.M., Wang M., Chan L., Yannopoulos C.G., Bilimoria D., et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J Biol Chem 280 (2005) 18202-18210
7. Lauer G.M., and Walker B.D. Hepatitis C virus infection. N Engl J Med 345 (2001) 41-52
8. Yao E., and Tavis J.E. A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol J 2 (2005) 88
9. Krieger N., Lohmann V., and Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 75 (2001) 4614-4624
10. McHutchison J. STAT-C: role in HCV treatment algorithm in 2008. In: Hep DART 2007.
11. Ferenci P., Fried M.W., Shiffman M.L., Smith C.I., Marinos G., Goncales Jr. F.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43 (2005) 425-433
12. Jensen D.M., Morgan T.R., Marcellin P., Pockros P.J., Reddy K.R., Hadziyannis S.J., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43 (2006) 954-960
13. Zeuzem S., Buti M., Ferenci P., Sperl J., Horsmans Y., Cianciara J., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44 (2006) 97-103
14. Sulkowski M.S., Lawitz E., Schiffman M.L., Muir A.J., Galler G., McCone J., et al. Final results of the IDEAL (Individualized Dosing Efficacy versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy) Phase IIIb study. J Hepatol 48 (2008) S370-S371
15. Kwo P., Lawitz E., McCone J., Schiff E.R., Vierling J., Pound D., et al. Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus PegIntron (Peginterferon alpha-2b)/ribavirin in treatment naive subjects with genotype-1 CHC. J Hepatol 48 (2008) S372
16. Jacobson I.M., Everson G., Gordon S.C., Kauffmann R.H., McNair L., Muir A., et al. Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naiive subjects with hepatptis C. Hepatology 46 (2007) 315A-316A
17. Lawitz E., Nguyen T., Younes Z., Santoro J., Gitlin N., McEniry D., et al. Valopicitabine (NM283) plus peg-interferon in treatment-naive hepatitis C participants with HCV genotype-1 infection: HCV RNA clearance during 24 weeks of treatment. Hepatology 44 (2006) 223A
18. Jacobson I.M., Ghalib R., Lawitz E., Freilich B., Gordon S.C., and Kwo P. Early viral response and on treatment response to CPG 10101 (Actilon), in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected participants with prior relapse response. Hepatology 44 (2006) 224A-225A
19. Nicolas O., Boivin G., St-Denis C., and Bedard J. Genotypic analysis of HCV NS5B variants from participants treated with VCH-759. J Hepatol 48 (2008) S317
20. David M, Nicolas O, Fex P, Billimoria D, L'Heureux L, Bedard J. Combination studies of VCH-916, a novel allosteric inhibitor of HCV NS5B polymerase, with interferon-a2a. In: 15th International Symposium on Hepatitis C Virus and Related Viruses; 2008 October 5-9, 2008; San Antonio, TX, USA; 2008.